Yutong Opens Its First Comprehensive Service Center in Europe

The Norway-based facility integrates maintenance, inspection, and parts supply to support battery-electric bus fleets throughout the vehicle lifecycle

STOKKE, Norway, Sept. 10, 2026 /PRNewswire/ -- Yutong Bus officially opened its first Yutong Service Center (the "Center") in Europe on September 8 in Stokke, Norway, integrating vehicle delivery, after‑sales service, spare parts supply, and professional training into one hub.

As Norway advances its transition to electric public transport, the Center will enhance maintenance capabilities, compliance inspections, and local service responsiveness for pure electric buses, offering customers a more direct service option and delivering systematic support for fleet operations across their full lifecycle.

Covering approximately 38,941 square meters with a building area of 6,074 square meters, including a 2,300‑square‑meter parts warehouse, the Center integrates brand display, vehicle delivery, after‑sales service, parts supply, and training facilities, delivering all‑around customer support. Built around Yutong as the core, the Center consolidates multi‑dimensional service functions and complements existing local partners and service channels, offering customers more direct, flexible issue resolution and service options.

"The service center is positioned as a comprehensive, centralized service hub, with a large inventory of parts, inspection facilities, professional service bays, and dedicated training equipment," said Jack Li, CEO of Yutong Central and Northern Europe. "Through efficient operations, we aim to help reduce customers' total cost of ownership and maximize bus uptime. By strengthening partnerships and expanding service coverage, we aim to deliver cost-effective services and create shared value while helping make public transport greener, smarter, and more inclusive."

One‑stop service ecosystem: from parts supply to integrated service support across the fleet lifecycle

With the local service center and dedicated on‑ground team, Yutong consolidates parts supply, fault diagnostics, maintenance, and professional training into a single service system, improving service efficiency and delivering full‑lifecycle fleet support for Norwegian passenger transport and bus operators. The Center features a comprehensive reception area, maintenance and repair zone, parts storage area, hands-on training space, vehicle display area, and brand experience zone, offering local customers an integrated service package spanning everything from vehicle sales and delivery to after‑sales repairs, parts supply, and technical training.

The Center features seven standardized maintenance bays, as well as dedicated bays for powertrain and large-component repairs, equipped with four‑post lifts, an electronic laser wheel alignment system, a brake tester, and a heavy‑duty tire balancer. It offers repair capabilities for chassis, electrical and high‑voltage systems, powertrains, air conditioning, and interiors, and can also handle non‑severe accident vehicles, alcohol interlocks, and tachographs.

Built to EU standards, the Center includes a dedicated bus inspection line for Norway's mandatory PKK annual inspections, featuring a 31.5‑meter pit, two 16‑ton pit jacks, and equipment for brake, lighting, side‑slip, and OBD testing, covering chassis, braking, safety devices, onboard diagnostics, and powertrain compliance. By conducting inspections, fault diagnosis, and safety checks locally, the Center helps customers reduce fleet downtime and lower operating costs.

It also has a 2,300‑square‑meter parts warehouse, covering 4,500 SKUs of Yutong genuine parts for battery, motor and electronic control systems, powertrains, chassis, steering systems, pneumatic and hydraulic systems, interior and exterior trim, wear parts, and maintenance consumables.

With local stock and regional distribution center replenishment, the Center reduces parts sourcing and repair waiting times, improving vehicle uptime and minimizing fleet downtime losses. All parts are backed by consistent quality and warranty standards, supported by a local engineering team delivering parts supply, diagnostics, and maintenance services.

Building local expertise: service, training, and long‑term fleet support

The Center also includes theoretical training rooms and hands-on training areas, with instruction led by experienced trainers. Equipped with a comprehensive whole-vehicle training platform for pure electric buses and dedicated training units for air conditioning, EBS braking, heaters, battery, motor and electronic control systems, and rear-axle disassembly, the Center supports training in component identification, operating principles, simulation, and fault diagnosis. The training equipment uses core assemblies and components sourced from actual vehicles, enabling customers' maintenance technicians to apply what they learn directly to real-world repairs.

Through its local team, standardized maintenance and inspection procedures, parts inventory and training capabilities, Yutong continues to deliver on its "EnRoute+" global service commitment. As Yutong's first comprehensive service center in Europe, the facility further underscores the company's long-term commitment to serving European customers. Building on the Norway service center, Yutong will continue to advance its localized service approach in markets including the Netherlands, Chile, Kazakhstan and Saudi Arabia. These efforts will strengthen local capabilities in electric bus repair, maintenance and inspection, improve service responsiveness, create more high-quality local jobs and support the electrification and low-carbon transition of public transport.

For more information on Yutong Service Center and "EnRoute+" global service commitment, please visit https://en.yutong.com/.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Yutong Opens Its First Comprehensive Service Center in Europe

Yutong Opens Its First Comprehensive Service Center in Europe

Yutong Opens Its First Comprehensive Service Center in Europe

CordenPharma accelerates sterile injectable CDMO manufacturing expansion with €80 million multi-year investment in new facility and additional aseptic fill & finish lines

BASEL, Switzerland, Sept. 10, 2026 /PRNewswire/ -- CordenPharma continues its ambitious long-term injectable CAPEX program at its FDA & EMA-approved Caponago (Milan), Italy site, reinforcing its position as a global leader in sterile injectable manufacturing. The expansion involves two key components to augment manufacturing capacity for sterile injectable drug products.

Firstly, the company has committed a multi-year €80 million investment into the future of injectable drug products, marking a significant milestone of that total with a €13 million acquisition of a new 11,000 m² commercial building and 26,000 m² of land, adjacent to its existing late-stage aseptic fill & finish manufacturing area. This expansion was finalized on 28 July 2026, increasing the site footprint by greater than 50%.

The new facility offers a blank canvas ideal for innovators seeking fit-for-purpose aseptic fill & finish CDMO outsourcing of their peptide, LNP, small molecule, biologic, and oligonucleotide-based injectable therapeutics, tailored to their specific production setups and requirements. The expanded capacity is a versatile foundation for the integration of additional manufacturing lines supporting a wide range of injectable formats including Pre-Filled Syringes (PFS), liquid or lyophilized vials, cartridges, and auto-injectors. Customers will also benefit from a single-site offering injectable solutions integrated with LNP manufacturing capabilities on the same campus at CordenPharma Caponago.

The space can accommodate a minimum of four aseptic fill & finish lines, four visual inspection lines, and four additional packaging lines, with options for customer-owned lines, large-scale lyophilization, and auto-injector assembly.

Secondly, over the past two years, CordenPharma has embarked on a series of strategic expansions at an existing operational area within its Caponago site that immediately contributes to the increased injectable capacity by adding two new aseptic fill & finish isolator lines. These include:

• A clinical and small-scale commercial combo line from Bausch & Ströbel for Pre-Filled Syringes (PFS), vials, and cartridges.
• A high-speed PFS & cartridge line from Syntegon, capable of producing >500,000 units per day.
• Expansion of the automatic secondary packaging area for PFS, vials, and ampoules.
• A doubling of analytical capacity to support growing project pipelines.

Completion of the new isolator lines is targeted for mid-2027 and 2028 respectively, ensuring CordenPharma remains at the forefront of sterility assurance and long-term compliance during sterile injectable manufacturing.

The investment in these new and expanded facilities underscores a proactive approach to addressing the global healthcare industry's increasing need for specialized injectable manufacturing. With these combined investment milestones bolstering a landmark scale-up in production with a projected total capacity up to 500 million injectable units per year, CordenPharma is poised to support innovators across their injectable drug lifecycle from early-phase projects to large-scale commercial production.

This capacity surge helps meet the rising global demand for sterile injectable outsourcing across therapeutic areas such as oncology, obesity, diabetes and Inflammatory diseases with complex modalities such as peptide-based GLP-1 therapeutics, oligonucleotides, LNPs, biosimilars and other biologics.

The company's customers will also gain valuable access to integrated solutions from drug substance to drug products, leveraging CordenPharma's global facility network and expertise in manufacturing peptides (including oral peptide drug products), oligonucleotides, non-viral carriers such as LNPs, and small molecules, including both highly potent and non-potent APIs.

Dr. Michael Quirmbach, President & CEO of CordenPharma Group, commented: "The support of our shareholders, Astorg, underscores our commitment to advancing sterile injectable manufacturing at CordenPharma Caponago. This strategic investment strengthens our leadership in the manufacture of drug products using complex modalities and enhances our end-to-end supply capabilities to meet rising global demand for injectable outsourcing, ultimately enabling partners to bring vital drug products in key therapeutic areas to patients more efficiently."

About CordenPharma

CordenPharma is a CDMO supporting and partnering with biotech and pharma innovators of complex modalities in the advancement of their drug development lifecycle. Harnessing the collective expertise of the teams across its globally integrated facility network, CordenPharma provides bespoke outsourcing services spanning the complete supply chain, from early clinical-phase development to commercialization.

With scientific expertise and partnership at its core, CordenPharma provides customers with high-value, end-to-end services with a strategic focus on Peptides, Small Molecules (both Highly Potent and Regular Potency), customized Lipid Excipients, Lipid NanoParticles (LNPs), sterile Injectables, and Oligonucleotides.

The CordenPharma Group is comprised of 13 facilities across Europe, North America and Asia with more than 3,500 employees. In the 2025 financial year, the organization generated sales of €960. In 2022, CordenPharma was acquired by Astorg - a leading Pan-European private equity firm with deep expertise in the healthcare sector - to accelerate its development and further strengthen its leadership in the CDMO space.

Please visit cordenpharma.com for more information I Follow CordenPharma on LinkedIn.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

CordenPharma Boosts Aseptic Fill-Finish Capacity to 500 Million Sterile Injectable Units Per Year